Can Peptide Drugs Really Be Taken as Tablets? The Race to Make GLP-1 and Other Peptides Oral

Peptide drugs have one major practical problem:

the digestive system is designed to break peptides down.

That is why so many peptide medicines are injected.

The stomach and intestine expose peptides to:

• acid
• digestive enzymes
• mucus
• poor membrane permeability
• variable gastrointestinal conditions

All of these make oral absorption difficult.

But researchers are increasingly finding ways around the problem.

In 2026, oral peptide delivery has become one of the most active areas of drug-development research, with new approaches involving:

• absorption enhancers
• enteric capsules
• lipid carriers
• enzyme protection
• peptide modification
• ingestible delivery devices

A 2026 review described oral peptide delivery as moving rapidly from a formulation problem toward a combination of pharmaceutical science, bioengineering and smart delivery technology. (PubMed⁠)

Why Can’t Most Peptides Simply Be Swallowed?

Peptides are chains of amino acids.

The gastrointestinal system is specifically designed to break proteins and peptides into smaller components.

That means an orally swallowed peptide may face degradation from:

• stomach acid
• pepsin
• pancreatic enzymes
• intestinal proteases

before it ever has a chance to enter the bloodstream.

Even If a Peptide Survives Digestion, Why Is Absorption Difficult?

The intestinal wall creates another barrier.

Peptides are generally:

• relatively large
• water-soluble
• electrically charged
• poorly able to cross cell membranes

Small lipophilic drugs can often move through the intestinal lining relatively easily.

Peptides usually cannot.

This produces extremely low oral bioavailability.

What Does Bioavailability Mean?

Bioavailability describes how much of a drug reaches systemic circulation in an active form.

An injected peptide avoids most of the gastrointestinal barriers.

An oral peptide does not.

Even successful oral peptide formulations may therefore absorb only a very small percentage of the swallowed dose.

A 2026 review of the absorption enhancer SNAC concluded that oral peptide bioavailability remains low and variable, even when specialised enhancers are used. (PubMed⁠)

So How Does Oral Semaglutide Work?

Oral semaglutide provides one of the best-established examples.

Semaglutide itself is still a peptide.

The tablet includes an absorption enhancer called:

SNAC — salcaprozate sodium.

SNAC modifies the local environment around the tablet and helps semaglutide cross the gastrointestinal barrier.

Its proposed actions include:

• changing local pH
• protecting peptide from degradation
• influencing membrane permeability
• promoting local absorption

The result is enough semaglutide entering circulation to create a therapeutic effect, despite the absolute absorption remaining low. (PubMed⁠)

Does the Whole Tablet Get Absorbed?

No.

Only a small proportion of the peptide dose reaches systemic circulation.

This is why oral peptide doses can be much larger numerically than injected doses.

The tablet has to compensate for the enormous losses occurring during digestion and absorption.

Why Is Oral Peptide Absorption So Variable?

Many factors can change absorption.

These include:

• whether food is present
• how much water is taken
• stomach emptying
• stomach pH
• intestinal transit
• formulation differences

This is why some oral peptide treatments have relatively strict instructions around eating and drinking.

Is This Different From Oral Small-Molecule GLP-1 Drugs?

Completely.

This distinction is increasingly important.

There are now two very different ways of creating an oral GLP-1 treatment.

Oral peptide

The drug itself is still a peptide.

It requires specialised technology to survive and cross the digestive tract.

Oral semaglutide is the classic example.

Oral small molecule

The drug is not a peptide.

It is a much smaller chemical compound engineered to activate the GLP-1 receptor after conventional oral absorption.

Orforglipron is an example of this strategy.

A 2026 review describes these as fundamentally different approaches to oral incretin treatment. (PubMed⁠)

Why Not Just Replace All Peptides With Small Molecules?

Because peptides have advantages.

Peptides can often reproduce the shape and activity of natural hormones with high receptor specificity.

That can make them particularly useful for:

• GLP-1
• GIP
• glucagon
• amylin
• multi-receptor agonism

Small molecules may interact with receptors differently.

So rather than one strategy replacing the other, both are developing in parallel.

What Is an Enteric Capsule?

An enteric capsule is designed to resist breakdown in the stomach.

Instead, it opens further along the gastrointestinal tract.

This can help protect sensitive drugs from:

• gastric acid
• stomach enzymes

Researchers can then release the peptide together with an absorption enhancer at a more favourable site.

What Did the 2026 Exenatide Study Do?

A particularly interesting 2026 study developed a two-layer protection strategy for oral exenatide.

Researchers first modified the peptide so that it interacted more effectively with lipid material.

They then placed it in a lipid-based formulation containing absorption-enhancing ingredients.

Finally, the formulation was placed inside an enteric capsule.

The approach aimed to:

1. protect the peptide from stomach degradation
2. prevent premature release
3. protect it from digestive enzymes
4. enhance intestinal permeability. (PubMed⁠)

Did It Work?

In laboratory testing, the formulation substantially improved protection against enzymatic degradation.

The researchers described it as a promising proof-of-concept platform.

However, this was still primarily a formulation study.

Further in-vivo testing is needed to establish how much peptide ultimately reaches the bloodstream and whether the approach produces useful therapeutic effects. (PubMed⁠)

What Is Hydrophobic Ion Pairing?

This is one of the clever techniques used in oral peptide research.

Peptides are normally very water-soluble.

That makes them poorly compatible with lipid delivery systems.

Researchers can pair a charged peptide with another molecule to make the overall complex more lipid-friendly.

This is called:

hydrophobic ion pairing.

In the 2026 exenatide work, this dramatically increased the peptide’s lipophilicity and allowed it to be incorporated into a lipid formulation. (PubMed⁠)

Why Use Lipids?

Lipids can potentially:

• protect peptides from digestive enzymes
• improve stability
• interact favourably with intestinal membranes
• carry permeation enhancers

This makes lipid-based systems an attractive approach for drugs that normally cannot cross the intestinal wall easily.

What Are Permeation Enhancers?

Permeation enhancers temporarily make it easier for a drug to cross the gastrointestinal barrier.

Examples include:

• SNAC
• sodium caprate
• other surfactant-like compounds

The challenge is producing enough permeability to improve absorption without damaging the intestinal barrier.

That balance is central to oral peptide development.

What About Enzyme Inhibitors?

Another strategy is to temporarily reduce the activity of digestive enzymes around the drug.

If the peptide is broken down more slowly, more of it may remain intact long enough to be absorbed.

But systemic inhibition of digestive enzymes could create unwanted effects.

That is why researchers generally try to make the effect:

• local
• temporary
• formulation-specific

rather than suppressing digestion broadly.

Can Nanoparticles Deliver Peptides?

Potentially.

Researchers are exploring:

• lipid nanoparticles
• polymer nanoparticles
• micelles
• vesicles
• bioadhesive carriers

These can encapsulate peptides and protect them as they pass through the gastrointestinal tract.

Some are also designed to interact with mucus or intestinal cells to improve delivery.

A 2026 review highlighted multifunctional carrier systems as one of the major future directions for oral peptide technology. (PubMed⁠)

What Is the Mucus Problem?

The intestine is coated in mucus.

This provides another protective barrier.

A delivery particle that sticks too strongly to mucus may never reach the intestinal wall.

But one that moves through mucus too easily may not remain in contact with the absorption site for long enough.

Researchers are therefore designing carriers that balance:

mucus penetration

with

intestinal adhesion.

Could Peptides Be Injected From Inside the Stomach?

Strangely enough, yes.

This is one of the more futuristic approaches.

Researchers have developed ingestible devices that are swallowed like capsules.

Once they reach the stomach or intestine, the device can mechanically deliver the drug through the gastrointestinal lining.

In effect:

the patient swallows a capsule, but the peptide is still injected internally.

Device-assisted delivery was highlighted as an important emerging area in a 2026 oral peptide review. (PubMed⁠)

Why Would That Be Useful?

Because the patient experiences the treatment as an oral tablet or capsule.

But the drug avoids the need to cross the gastrointestinal barrier naturally.

This could potentially allow larger peptide molecules to be delivered orally without sacrificing as much bioavailability.

Could Amylin Eventually Become Oral?

Potentially.

There is no biological reason the oral-delivery problem applies only to GLP-1.

Amylin analogues face many of the same challenges:

• enzymatic degradation
• poor permeability
• molecular size

If oral peptide-delivery technology continues improving, compounds targeting:

• amylin
• GIP
• glucagon
• multiagonist pathways

could potentially be formulated orally as well.

What About Zenagamtide?

Zenagamtide is particularly interesting because its programme includes both:

• injectable
• oral

development.

Because it combines amylin-related and GLP-1 activity within one molecule, successful oral development would demonstrate that even more sophisticated multi-pathway peptide designs may eventually be delivered without injections.

What About Oral Ecnoglutide?

Ecnoglutide is another example of this emerging trend.

An oral ecnoglutide tablet programme is being studied in humans.

A Phase 1 study has investigated oral ecnoglutide tablets in healthy participants, and another trial registered in 2026 is evaluating oral ecnoglutide in people with obesity or overweight. (anzctr.org.au⁠)

That makes ecnoglutide particularly relevant because it represents an attempt to move a modern engineered peptide from injection into tablet form.

What Is the New VRB-101 Combination Trial?

A 2026 clinical trial is testing oral ecnoglutide, known as VRB-101, either alone or alongside another oral metabolic compound called VRB-103.

The study plans to evaluate:

• safety
• tolerability
• pharmacokinetics
• pharmacodynamic effects

in people with obesity or overweight. (clinicaltrials.gov⁠)

This is important because oral drug development is already beginning to extend from single agents into oral combination therapy.

Why Is This Important for Multi-Agonists?

Multi-receptor peptides can become structurally larger and more complex.

That makes oral absorption even harder.

Future scientists therefore face two engineering problems simultaneously:

1. design the ideal receptor profile
2. get the molecule into the bloodstream

A perfect multiagonist is not very useful as an oral drug if virtually none of it can survive digestion.

Could Oral Peptides Ever Match Injections?

Possibly.

A 2026 systematic review found that high-dose oral semaglutide produced placebo-subtracted weight reduction approaching that of injectable semaglutide in clinical trials. (PubMed⁠)

That demonstrates that low bioavailability does not necessarily prevent strong clinical effectiveness if the formulation and dose are engineered correctly.

Why Are Higher Oral Doses Needed?

Because most of the swallowed peptide never reaches circulation.

Imagine an injected treatment delivers nearly all of the administered dose directly into tissue.

An oral formulation may deliver only a small fraction.

So developers compensate by administering more peptide orally.

This can increase:

• manufacturing requirements
• formulation complexity
• cost

which is another reason improving bioavailability matters.

Could Oral Treatment Improve Adherence?

Potentially.

Some people dislike:

• needles
• injection devices
• refrigeration
• travelling with injectable medication

A tablet can be much simpler.

A 2026 review highlighted fear of injections as one reason oral GLP-1 therapies could improve acceptance for some patients. (PubMed⁠)

But oral treatment introduces its own inconveniences if it requires strict fasting or timing rules.

Are Oral Peptides Automatically Easier to Manufacture?

No.

They may actually be more difficult.

Developers may need:

• much larger peptide doses
• complex absorption enhancers
• protective coatings
• specialised capsules
• highly controlled manufacturing

So removing the injection device does not necessarily make the drug simpler.

What Are the Safety Questions?

Researchers need to establish whether chronic use of absorption enhancers affects:

• intestinal barrier function
• inflammation
• gut microbiota
• nutrient absorption

A 2026 review of SNAC concluded that the enhancer has substantial clinical experience but that some newer preclinical findings involving microbiome and inflammatory changes still require investigation. (PubMed⁠)

Could Oral Delivery Change How Often Peptides Are Taken?

Potentially.

Oral drugs do not necessarily need to last a week.

They may instead be taken:

• daily
• several times per week
• using modified-release technology

This could allow shorter-acting molecules to be practical because taking a tablet every day is often easier than giving an injection every day.

Will Monthly Injections or Daily Tablets Win?

There may not be one winner.

Future metabolic treatment could include:

weekly injections

monthly injections

daily tablets

oral peptide capsules

oral small-molecule agonists

Different people may prefer different options.

Convenience will be balanced against:

• efficacy
• tolerability
• cost
• adherence
• dosing restrictions

What Is the Difference Between an Oral Peptide and an Oral Peptidomimetic?

A peptide is still made from amino-acid chains.

A peptidomimetic is a molecule engineered to reproduce important features of a peptide without being a conventional peptide itself.

A 2026 review identified peptidomimetic design as another potential route toward oral metabolic therapies. (PubMed⁠)

This could blur the traditional distinction between peptide medicines and small molecules.

Could the Future Be Mostly Oral?

Possibly, but injections are unlikely to disappear.

Injectables provide major pharmacological advantages:

• reliable bioavailability
• predictable exposure
• long duration
• simpler peptide formulation

Oral treatment trades some of that pharmacological simplicity for greater convenience.

The two approaches are likely to coexist.

Why Is Oral Delivery Especially Important for Chronic Treatment?

Metabolic therapies may be used for years.

Over decades, small differences in convenience can become important.

A treatment requiring:

365 tablets per year

might be preferable to weekly injections for one person.

Another person may prefer:

12 monthly injections

rather than remembering a tablet every day.

Long-term treatment is likely to become increasingly personalised around these preferences.

The Bigger Picture

Peptide engineering is advancing on two fronts.

Scientists are changing what peptides do by creating:

• dual agonists
• triple agonists
• amylin combinations
• biased agonists

At the same time, they are changing how peptides are delivered.

That second revolution receives less attention, but it could be just as important.

A highly effective peptide that requires inconvenient administration may have less real-world impact than a slightly less powerful treatment that people can reliably take for years.

The Bottom Line

Peptides are difficult to turn into tablets because the gastrointestinal system:

• breaks them down
• blocks their absorption
• exposes them to highly variable conditions

But researchers are increasingly overcoming those barriers through:

• absorption enhancers
• enteric capsules
• lipid formulations
• hydrophobic ion pairing
• nanoparticles
• enzyme protection
• ingestible delivery devices. (PubMed⁠)

Oral semaglutide has already demonstrated that a peptide can be delivered effectively through the gastrointestinal tract despite low absolute bioavailability.

And newer programmes involving compounds such as oral ecnoglutide show that researchers are now attempting to extend the principle to more advanced engineered peptides. (clinicaltrials.gov⁠)

The next major step may be even more ambitious:

oral multi-receptor peptides combining GLP-1, GIP, glucagon or amylin activity within a single tablet.

If oral-delivery technology continues to improve, one of the defining changes in next-generation peptide research may not simply be what receptor a molecule targets.

It may be that increasingly sophisticated peptides no longer need to be injected at all.

This article is for research and educational purposes only. Several oral peptide technologies and compounds discussed remain investigational.